Patents by Inventor Beatrice Gaugler

Beatrice Gaugler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isolated proteins MAGE-4 and MAGE-41
    Publication number: 20100009437
    Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.
    Type: Application
    Filed: January 12, 2009
    Publication date: January 14, 2010
    Inventors: Beatrice Gaugler, Benoit Van den Eynde, Pierre van der Bruggen, Thierry Boon-Falleur
  • Isolated proteins MAGE-4 and MAGE-41
    Publication number: 20060127356
    Abstract: The invention relates to nucleic acid molecules which code for the tumor rejection antigen precursor MAGE-3. Also disclosed are vectors, cell lines, and so forth, which utilize the nucleic acid molecule, and optionally, molecules coding for human leukocyte antigen HLA-A1. Uses of these materials in therapeutic and diagnostic contexts are also a part of the invention.
    Type: Application
    Filed: October 17, 2005
    Publication date: June 15, 2006
    Inventors: Beatrice Gaugler, Benoit Eynda, Pierre der Bruggen, Thierry Boon-Falleur
  • Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules
    Patent number: 6379901
    Abstract: The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: April 30, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurguin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Isolated nonapeptides presented by HLA molecules, and uses thereof
    Patent number: 6222012
    Abstract: The invention involves nonapeptides bound by HLA molecules such as HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: February 23, 1995
    Date of Patent: April 24, 2001
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre Van der Bruggen, Etienne De Plaen, Christoph Lurquin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde, Pedro Romero
  • Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof
    Patent number: 5939526
    Abstract: The invention describes the RAGE tumor rejection antigen precursor family, including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a RAGE tumor rejection antigen precursor.
    Type: Grant
    Filed: September 20, 1995
    Date of Patent: August 17, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Beatrice Gaugler, Benoit Van den Eynde, Peter Schrier, Nathalie Brouwenstijn, Thierry Boon-Falleur
  • Isolated cytolytic T cells specific for complexes of MAGE related peptides and HLA molecules
    Patent number: 5695994
    Abstract: The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by HLA molecules HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: December 9, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurguin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
    Patent number: 5512437
    Abstract: A method for determining head and neck squamous cell carcinomas, bladder tumors and prostate carcinomas is described. The method involves assaying for expression of the gene coding for tumor rejection antigen precursor MAGE-3, or its expression product. Various assays, and kits useful for these assays, are described.
    Type: Grant
    Filed: March 1, 1994
    Date of Patent: April 30, 1996
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Beatrice Gaugler, Thierry Boon-Falleur, Benoit van den Eynde, Etienne DePlaen, Francis Basseur, Bernard Lethe, Pierre van der Bruggen
  • Isolated nucleic acid molecules which encode MAGE derived nonapeptides
    Patent number: 5462871
    Abstract: The invention relates to isolated nucleic acid molecules which encode nonapeptides derived from MAGE tumor rejection antigen precursors. The nonapeptides form complexes with human leukocyte antigens presented on the surfaces of cells, and lead to lysis of these cells by cytolytic T lymphocytes. Thus, they are useful in diagnostic methods. Also a part of the invention are vectors which are designed to encode the nonapeptides as well as cell lines which have been transformed or transfected with the isolated nucleic acid molecules of the invention, or vectors including these molecules.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: October 31, 1995
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurquin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde